ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)

• Private placement includes participation of EQT Life Sciences, which is expected to make an EUR 25M investment
• Stifel Europe Securities SAS to act as Sole Global Coordinator and, together with Bank Degroof Petercam SA/NV, as Joint Bookrunners of the Private Placement
• Pricing will be established through a bookbuilding exercise led by the Joint Bookrunners
  
  

EINDHOVEN, the Netherlands, April 15, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces the launch of a capital increase by way of a bookbuild offering through a private placement with institutional investors (the “Private Placement”) via the Joint Bookrunners (as defined below) of ordinary shares in the Company’s issued share capital (such shares the “New Shares”). The Private Placement includes the participation of EQT Life Sciences, which is expected to make an EUR 25M investment. The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Private Placement through a bookbuilding exercise. The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights. The Company intends to raise gross proceeds of approximately EUR 40M from the Private Placement.

ONWARD currently envisions using the net proceeds of the Private Placement, together with its existing cash balance, to:

• Fund development initiatives, including but not limited to product development, clinical studies and regulatory activities for the investigational ARC-IM System to address blood pressure instability in people with spinal cord injury (40%);
• Expand sales efforts and related operations to support commercialization of the ARC-EX System in the US, Europe and select other geographies (30%);
• Support and scale quality and administrative activities (20%); and
• Support working capital, general corporate purposes, and the servicing of existing debt obligations (10%).